Unlabelled: Amiodarone via iodine excess can determine thyroid dysfunction.
Aim: to assess thyroid dysfunction in patients treated with amiodarone, according to previous daily iodine intake.
Material And Methods: 63 patients treated with amiodarone were assessed. 11 of 63 were resident in a moderate iodine deficient area. Thyroid stimulating hormone (TSH), free and total thyroxine (T4) and total triiodothyronine (T3) were measured. Thyroid ultrasonography, color flow Doppler sonography (CFDS), radioiodine uptake (RAIU) at 2 and 24 hours were also performed.
Results: Amiodarone-induced thyrotoxicosis developed in 31 patients (49.2%); 17 patients (27%) remained euthyroid. Patients from iodine deficient areas developed more frequent hyperthyroidism (91% vs. 40.4%), at significant lower cumulative doses of amiodarone, and never hypothyroidism. Overt hyperthyroidism prevails (29/31 patients). Frequency of amiodarone-induced thyrotoxicosis type I was 19% (12/63), type II 12.7% (8/63), and of mixed forms 17.5% (11/63), without significant differences between the two geographical areas. There are no peculiar features of amiodarone-induced thyrotoxicosis versus common hyperthyroidism, but there is a tendency at recurrence of tachyarrhythmias at lower levels of T3 than in common hyperthyroidism. Amiodarone-induced hypothyroidism developed in 15 patients (23.8%) and none was from iodine deficient areas, but almost half show high levels of antithyroid peroxidase antibodies (ATPO). Subclinical hypothyroidism prevails (11/15 patients).
Conclusion: a predictor for amiodarone-induced thyroid dysfunction is iodine deficiency in nutrition.
Download full-text PDF |
Source |
---|
Dig Dis Sci
January 2025
Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital, 75 Francis Street, Boston, MA, 02115, USA.
Background: Chronic constipation, diarrhea, and fecal incontinence (FI) are prevalent with significant impact on quality of life and healthcare utilization. Thyroid dysfunction was recognized as a potential contributor to bowel disturbances in selected populations, but the strength/consistency of this association remain unclear.
Aims: To investigate the relationship between thyroid function and bowel health measures (constipation, diarrhea, and FI) in a nationally representative sample of the U.
Occup Med (Lond)
January 2025
Department of Occupational and Environmental Health, Ministry of Education Key Lab of Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, PR China.
Background: Shift work is associated with an increased risk of liver injury. However, whether and how shift work alters liver function remains unclear.
Aims: This study aimed to investigate the associations between shift work and the liver function parameters, and further explore the mediating roles of thyroid function indicators.
Clin Nutr
January 2025
Department of Food Safety, Centre of Sustainable Diets, Norwegian Institute of Public Health, P.O. Box 222, NO-0213 Oslo, Norway. Electronic address:
Background & Aims: Iodine deficiency is linked to multiple adverse health outcomes, but there is scarce knowledge regarding iodine intake and development of chronic hypertension. We aimed to investigate the prospective association between habitual dietary iodine intake and pharmacologically treated hypertension in mothers up to 10 years after delivery.
Methods: The present study is based on data from an ongoing pregnancy cohort and includes 58,629 women without thyroid dysfunction and hypertension at baseline.
J Pediatr Endocrinol Metab
January 2025
Department of Pediatric Pulmonology, Dicle University, Diyarbakır, Türkiye.
Objectives: There is limited research on thyroid function in pediatric patients with cystic fibrosis (pwCF). This study aimed to determine the frequency of thyroid dysfunction in children and adolescents with CF and to evaluate iodine deficiency and selenium status in pwCF.
Methods: Sixty-two CF patients and 62 control subjects were evaluated.
J Gastroenterol Hepatol
January 2025
Department of Pharmacology, Hepatology and Molecular Medicine Lab, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences (SIMATS), Chennai, Tamil Nadu, India.
Background: Resmetirom, the first FDA-approved drug for nonalcoholic steatohepatitis (NASH) with fibrosis in obese patients, when combined with lifestyle modifications, improves NASH resolution and reduces fibrosis by at least one stage. Low thyroid hormone (T) levels are linked to a higher risk of developing metabolic dysfunction-associated steatotic liver disease (MASLD). Epidemiological studies have confirmed the positive correlation between hypothyroidism and MASLD.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!